Klotho-FGF23, Cardiovascular Disease, and Vascular Calcification: Black or White?

Author(s): Giuseppe Cianciolo, Andrea Galassi, Irene Capelli, Roberto Schillaci, Gaetano La Manna, Mario Cozzolino*

Journal Name: Current Vascular Pharmacology

Volume 16 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Patients affected by Chronic Kidney Disease and Mineral Bone Disorder (CKD-MBD) have a high risk of cardiovascular (CV) mortality that is poorly explained by traditional risk factors. The newest medical treatments for CKD-MBD have been associated with encouraging, but still inconsistent, improvement in CV disease complications and patient survival. A better understanding of the biomarkers and mechanisms of left ventricular hypertrophy (LVH), atherosclerosis, and vascular calcification (VC) may help with diagnosis and treatment of the organ damage that occurs secondary to CKD-MBD, thus improving survival. Recent insights about fibroblast growth factor-23 (FGF23) and its co-receptor, Klotho, have led to marked advancement in interpreting data on vascular aging and CKDMBD.

Conclusion: This review will discuss the current experimental and clinical evidence regarding FGF23 and Klotho, with a particular focus on their roles in LVH, atherosclerosis, and VC.

Keywords: Kidney disease, vascular calcification, bone disease, CKD, CV, VC.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 09 March, 2017
Page: [143 - 156]
Pages: 14
DOI: 10.2174/1570161115666170310092202
Price: $65

Article Metrics

PDF: 122
HTML: 18
PRC: 3